Wallace E M, Gow S M, Wu F C
Department of Clinical Biochemistry, Royal Infirmary Edinburgh, Scotland.
J Clin Endocrinol Metab. 1993 Jul;77(1):290-3. doi: 10.1210/jcem.77.1.8325955.
Sex-steroid based male contraceptive regimes induce azoospermia in only 40-70% of Caucasian men. The reason(s) why the remainder maintains a low level of spermatogenesis (oligozoospermia) despite gonadotrophin suppression is unclear. In order to improve our understanding of this phenomenon, we examined the changes in sperm density and plasma LH, FSH, testosterone (T), oestradiol (E2), and inhibin (IN) in 28 normal men who received 200 mg testosterone enanthate (TE) im weekly during a male contraceptive efficacy trial. Gonadotrophins were measured by an ultrasensitive time-resolved immunofluorometric assay (DELFIA) with a sensitivity of 0.04 U/L, to determine the adequacy of suppression. Seventeen of the 28 men achieved azoospermia; the other 11 remained oligozoospermic (sperm density 3.3-4.7 x 10(6)/mL) after 6 months of TE exposure. Azoospermic subjects displayed a more rapid decline in sperm density, a significant difference being apparent by 5 weeks after starting TE. During TE treatment, both LH and FSH were consistently suppressed to below the limits of detection, whereas there was a 2.5-fold rise in T and E2 with a similar decrease in IN. There were no consistent differences in any of these hormone concentrations between the azoospermic and oligozoospermic groups. Recovery of sperm density to baseline levels or above 20 x 10(6)/mL was significantly slower in the azoospermic group. During the recovery phase, the azoospermic men exhibited significantly higher LH and FSH levels compared to baseline and to the oligozoospermic subjects even though no differences in circulating T, E2, or IN were observed. We conclude that incomplete gonadotrophin suppression or differences in sex steroid or inhibin levels are unlikely to be responsible for the maintenance of minor degrees of spermatogenesis in some men during TE administration. The rebound rise in gonadotrophins in azoospermic but not oligozoospermic responders during recovery may reflect a more profound degree of spermatogenic suppression in the former group.
基于性类固醇的男性避孕方案仅能使40%至70%的白人男性出现无精子症。其余男性尽管促性腺激素受到抑制,但仍维持低水平精子发生(少精子症)的原因尚不清楚。为了更好地理解这一现象,我们在一项男性避孕效果试验中,对28名正常男性进行了研究,这些男性每周接受200毫克庚酸睾酮(TE)肌肉注射,我们检测了他们精子密度以及血浆促黄体生成素(LH)、促卵泡生成素(FSH)、睾酮(T)、雌二醇(E2)和抑制素(IN)的变化。促性腺激素采用超灵敏时间分辨免疫荧光分析法(DELFIA)进行测定,灵敏度为0.04 U/L,以确定抑制是否充分。28名男性中有17人达到无精子症;在接受TE治疗6个月后,另外11人仍为少精子症(精子密度为3.3 - 4.7×10⁶/mL)。无精子症受试者的精子密度下降更快,在开始TE治疗5周后差异明显。在TE治疗期间,LH和FSH均持续被抑制至检测限以下,而T和E2升高了2.5倍,IN则有类似程度的下降。无精子症组和少精子症组在这些激素浓度上均无一致差异。无精子症组精子密度恢复到基线水平或高于20×10⁶/mL的速度明显较慢。在恢复阶段,无精子症男性的LH和FSH水平相比基线以及少精子症受试者显著更高,尽管循环中的T、E2或IN未观察到差异。我们得出结论,促性腺激素抑制不完全或性类固醇或抑制素水平的差异不太可能是某些男性在TE给药期间维持轻度精子发生的原因。恢复期间,无精子症但非少精子症应答者的促性腺激素反弹升高可能反映了前一组精子发生抑制程度更深。